(b) a polynucleotide encoding a polypeptide comprising amino acids 100 to 130 of SEQ ID NO: 2;

(c) a polynucleotide encoding a polypeptide comprising amino acids 100 to 111 of SEQ ID NO: 1;

(d) a polynucleotide encoding a polypeptide comprising amino acids 100 to 110 of SEQ ID NO: 1;

(e) a polynucleotide encoding a polypeptide comprising amino acids 114 to 130 of SEQ ID NO: 1; and

(f) a polynucleotide capable of hybridizing to and which is at least 95% homologous to a polynucleotide of (a) through (e).

8. An isolated polypeptide selected from the group consisting of the amino acid sequence of SEQ ID NO: 1 and the amide thereof.

9. An isolated polypeptide selected from the group consisting of the amino acid sequence of SEQ ID NO: 2 and the amide thereof.

10. An isolated polypeptide selected from the group consisting of a polypeptide comprising the sequence of SEQ ID NO: 6, a polypeptide comprising amino acids 28 to 130 of SEQ ID NO: 2, and the amides thereof.

11. An isolated polypeptide comprising the sequence of SEQ ID NO: 13.

12. The isolated peptide of claim 11 wherein the isolated peptide is from about 28 amino acid residues to about 39 amino acid residues long.

13. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising the sequence of SEQ ID NO: 7;

(b) a polypeptide comprising the sequence of SEQ ID NO: 8;

(c) a polypeptide comprising amino acids 42 to 66 of SEQ ID NO: 1;

(d) a polypeptide comprising amino acids 42 to 65 of SEQ ID NO: 1;

(e) a polypeptide comprising amino acids 43 to 66 of SEQ ID NO: 1;

(f) a polypeptide comprising amino acids 43 to 65 of SEQ ID NO: 1;

(g) a polypeptide comprising at least one conservative amino acid substitution in the sequence of polypeptides (a-f); and

(h) the amides thereof.

14. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising the sequence of SEQ ID NO: 9;

(b) a polypeptide comprising the sequence of SEQ ID NO: 10; and

(c) the amides thereof.

15. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising amino acids 100 to 130 of SEQ ID NO: 1;

(b) a polypeptide comprising amino acids 100 to 130 of SEQ ID NO: 2;

(c) a polypeptide comprising amino acids 100 to 111 of SEQ ID NO: 1;

(d) a polypeptide comprising amino acids 100 to 110 of SEQ ID NO: 1;

(e) a polypeptide comprising amino acids 114 to 130 of SEQ ID NO: 1;

(f) a polypeptide comprising at least one conservative amino acid substitution in the sequence of polypeptides (a-e); and

(g) the amides thereof.

16. A vector comprising a polynucleotide of claim 1 operably linked to control sequences which direct the expression of the polynucleotide.

17. A vector comprising a polyfnucleotide of claim 2 operably linked to control sequences which direct the expression of the polynucleotide.

18. A vector comprising a polynucleotide of claim 3 operably linked to control sequences which direct the expression of the polynucleotide.

19. A vector comprising a polynucleotide of claim 4 operably linked to control sequences which direct the expression of the polynucleotide.

20. A vector comprising a polynucleotide of claim 5 operably linked to control sequences which direct the expression of the polynucleotide.

21. A vector comprising a polynucleotide of claim 6 operably linked to control sequences which direct the expression of the polynucleotide.

22. A vector comprising a polynucleotide of claim 7 operably linked to control sequences which direct the expression of the polynucleotide.

23. A host cell transformed with a vector of claim 16.

24. A host cell transformed with a vector of claim 17.

25. A host cell transformed with a vector of claim 18.

26. A host cell transformed with a vector of claim 19.

27. A host cell transformed with a vector of claim 20.

28. A host cell transformed with a vector of claim 21.

29. A host cell transformed with a vector of claim 22.

30. A pharmaceutical composition comprising a polypeptide of claim 8 and a pharmaceutically acceptable carrier.

31. A pharmaceutical composition comprising a polypeptide of claim 9 and a pharmaceutically acceptable carrier.

32. A pharmaceutical composition comprising a polypeptide of claim 10 and a pharmaceutically acceptable carrier.

33. A pharmaceutical composition comprising a polypeptide of claim 11 and a pharmaceutically acceptable carrier.

34. A pharmaceutical composition comprising a polypeptide of claim 14 and a pharmaceutically acceptable carrier.

35. A pharmaceutical composition comprising a polypeptide of claim 15 and a pharmaceutically acceptable carrier.

36. A method of treating a neurological disease or homeostatic dysfunction or controlling the production of a homeostatic regulatory hormone comprising introducing an effective amount of the composition of claim 18 into a mammal in need of such treatment.

37. An antibody that immunoreacts with an isolated mammalian H35 protein.

38. An antibody of claim 37 which is a monoclonal antibody.